<DOC>
	<DOCNO>NCT01086826</DOCNO>
	<brief_summary>This randomized multicenter open label phase III factorial trial evaluate 3 year OS patient locally advance squamous cell carcinoma head neck treat locoregional treatment ( radiotherapy plus concomitant chemotherapy cetuximab ) without neoadjuvant chemotherapy .</brief_summary>
	<brief_title>Treatment Patients With Locally Advanced Squamous Cell Carcinoma Head Neck</brief_title>
	<detailed_description>This multicenter open label randomise phase III study implementation previous phase II randomize trial evaluate efficacy chemoradiotherapy without neoadjuvant TPF chemotherapy locally advanced Head Neck cancer . Assuming randomisation ratio 1:1 , use Mantel-Cox version log-rank test , 204 event require order achieve power 0.80 detect hazard ratio 0.675 favour experimental treatment type I error 0.05 , two-sided . With uniform accrual 4 year follow-up 2 year , total number require patient 420 ( 210 per arm ) detect absolute difference 12 % 3 year overall survival favour neoadjuvant arm ( 52.5 % 64.5 % ) .Since 101 patient randomized phase II part study include final analysis , 319 new patient need complete trial.The total number 420 patient able detect difference 10 % , ( 35 % 45 % ) term grade 3/4 in-field mucosal toxicity concomitant treatment ( radiotherapy plus chemo cetuximab ) power 80 % . Within H &amp; N07 trial introduce sub-study allows investigate value circulate marker evaluation predictor response anti EGFR therapy patient cancer head neck . The expression level analysis circulate biological marker evaluate blood collect therapy . The analysis concern follow biological marker : Cytokines angiogenesis cell adhesion molecule ; Proteins involve EGFR signal pathway ( EGF , TGF-a , s-EGFR ) ; circulate tumor cell ( CTC ) circulate endothelial cell ( CEC ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . Histologically cytologically proven squamous cell carcinoma head neck . 2 . Primary tumor site eligible : oral cavity , oropharynx , hypopharynx Although admittedly squamous cell type , follow tumor exclude responsiveness chemotherapy : tumor nasal paranasal cavity nasopharynx . 3 . Stage 3 4 disease without evidence distant metastasis verify chest X Ray , abdominal ultrasound , CT ( liver function test abnormality ) ; bone scan case local symptom . 4 . At least one uni bidimensionally measurable lesion . 5 . Tumor consider inoperable evaluation multidisciplinary team ( i.e . surgeon , medical oncologist radiation oncologist ) . Criteria inoperability : 1. technical unresectability : tumor fixation/invasion base skull cervical vertebra , involvement nasopharynx , fix lymph node . 2 . Physician decision base low surgical curability . This category include follow : ) All T34 stage . ii ) All N23 stage exclude T1 N2 . iii ) Patients organ preservation . Reason inoperability record CRF . 6 . No previous chemotherapy radiotherapy reason previous surgery SCCHN ( biopsy ) allow time study entry . 7 . Age &gt; 18 year . 8 . Karnofsky performance status &gt; 70 . ( ECOG 01 ) ( Appendix II ) 9 . No active alcohol addiction . 10 . Life expectancy &gt; 6 month . 11 . Signed informed consent prior begin protocol specific procedure . 12 . Adequate bone marrow , hepatic renal function evidence follow : ) Hematology ( Bone marrow ) : ) Neutrophils &gt; 2.0 109/L ii ) Platelets &gt; 100 x 109/L iii ) Hemoglobin &gt; 10 g/dL b ) Hepatic function ) Total bilirubin &lt; 1 x UNL ii ) ASAT ( SGOT ) ALAT ( SGPT ) &lt; 2.5 x ULN iii ) Alkaline phosphatase &lt; 5 x ULN Patients ASAT ALAT &gt; 1.5 x ULN associate alkaline phosphatase &gt; 2.5 x ULN eligible study . c ) Renal function : serum creatinine &lt; 1 x UNL . In case borderline value creatinine clearance &gt; 60 ml/min ( calculate CockcroftGault method follow : 13 . Patients must available treatment followup . Patients register trial must treat follow participate center . 1 . Pregnant lactate woman woman childbearing potential use adequate contraception . 2 . Previous current malignancy site , exception adequately treat situ carcinoma cervix uterus , basal squamous cell carcinoma skin , cancer curatively treat surgery evidence disease least 5 year . Any prior treatment radiotherapy chemotherapy exclusion criterion . 3 . Symptomatic peripheral neuropathy &gt; grade 2 NCICCTG criterion 4 . Symptomatic alter hear &gt; grade 2 NCICCTG criterion . 5 . Other serious illness medical condition include : 1 . Unstable cardiac disease despite treatment , myocardial infarction within 6 month prior study entry . 2 . History significant neurologic psychiatric disorder include dementia seizure . 3 . Active uncontrolled infection . 4 . Active peptic ulcer . 5 . Hypercalcemia . 6 . Chronic obstructive pulmonary disease require hospitalization year precede study entry 6 . History hypersensitivity reaction polysorbate 80 ( Appendix IV ) 7 . Patients require intravenous alimentation . 8 . Patients experience weight loss 20 % body weight 3 month precede study entry . 9 . Concomitant treatment anticancer therapy . 10 . Participation therapeutic clinical trial within 30 day study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>